[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontitis":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,159,0,25,[9,54,80,109,138,166,193,221,248,267,282,313,334,366,390,410,430,449,472,507,536,557,585,607,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100625608","phase-2-xylitol-and-the-prevention-of-periodontal-disease-and-preterm-birth-trial-100625608",false,"NCT07424846","Xylitol and the Prevention of Periodontal Disease and Preterm Birth Trial","Xylitol and the Prevention of Periodontal Disease and Preterm Birth (XaPPP) Trial","XaPPP","Inclusion Criteria:\n\n* Able to provide informed consent. For those under 18 years of age, an approval will additionally be sought from the parent or guardian\n* Less than 20 weeks' gestation (by best obstetric estimate)\n* At least 20 natural teeth\n* Planning to deliver at one of the health facilities within the XaPPP trial\n* Receiving antenatal obstetric care at one of the 8 health districts\n* Willing to chew two pieces of gum thrice daily for 5 minutes after the morning, day and evening meals throughout pregnancy\n* Willing to attend all study visits\n* Willing to provide biospecimens (oral, vaginal, placental, breast milk)\n* Willing to undergo at least two dental exams including oral microbiota sampling at study enrolment \\\u003C20 weeks of pregnancy, 28-30 weeks of pregnancy, and 6-8 weeks after giving birth\n* Willing to have their child undergo follow up through at least 12 months after birth including neurodevelopmental examination(s)\n* Speaks Chichewa or English\n\nAll patients who meet inclusion criteria will be approached without regard to sex, race, ethnicity, parents' country of origin, or religious preferences.\n\nExclusion Criteria:\n\n* Those who upon screening and enrolment but dislike the taste of the gum and state they will not chew the gum throughout pregnancy\n* Gravidae with known or suspected non-viable pregnancy (including life threatening congenital anomalies such as cardiac, neurological or others)\n* Pregnant individual has a life-threatening diagnosis such as cancer requiring treatment during pregnancy\n* Pregnant women with a known or suspected morbidly adherent placenta (such as placenta accrete, increta and percreta)\n* Known allergy to xylitol","FEMALE",{"count":20,"type":21},6000,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The ground-breaking Prevention of Prematurity and Xylitol (PPaX) cluster randomized controlled clinical trial was conducted in Lilongwe, Malawi and enrolled approximately 10,069 pregnant individuals seeking to evaluate the impact of xylitol-containing chewing gum compared to no chewing gum on reducing the occurrence of maternal periodontal disease, preterm birth, and low birthweight offspring. The premise of this study centers upon the numerous publications supporting a strong association between maternal periodontal disease and preterm birth. Given that xylitol-containing chewing gum is considered a prebiotic and known to reduce cariogenic and periodontopathic bacteria, the study evaluated and discovered a statistically significant reduction in maternal periodontal disease, preterm birth, and low birthweight offspring among pregnant individuals who chewed xylitol-containing chewing gum.\n\nWhile PPaX demonstrated the efficacy of xylitol to reduce preterm birth (PTB), the study had important limitations: (a) PPaX was an unblinded cluster-randomized study with only 8 clusters, 4 with xylitol-containing chewing gum and 4 without any gum (not placebo-controlled); (b) PPaX used a suboptimal dose of 2 grams of xylitol daily which may have reduced the effectiveness of the intervention given that recent literature suggests 5-10 grams\u002Fday more effectively improve oral health; and (c) PPaX did not evaluate infant mortality nor early neurodevelopmental outcomes. Notably, reducing fetal exposure to periodontal disease (PD) as well as PTB may improve neurodevelopmental outcomes for offspring as both prematurity and fetal exposure to inflammation are well-documented risk factors for neurodevelopmental delay (NDD) and infant mortality.\n\nThe investigators will conduct a double-blind, placebo-controlled, individually randomized clinical trial with 3 arms among Malawian pregnant individuals (n=6000) at \\\u003C20 weeks of pregnancy with the co-primary outcomes being the incidence of PTB and low birthweight offspring. The 3 study arms (n=2000 each) will be (a) an optimized dose of xylitol-containing chewing gum (6.4 grams\u002Fday), (b) the PPaX trial xylitol dose (2.1 grams\u002Fday), or (c) flavored sorbitol gum base (placebo control). This trial overcomes the PPaX trial's limitations and will definitively answer whether xylitol prevents PTB in Malawi. The investigators will additionally collect biospecimens from a random sampling of the participants for biobanking for later analysis of inflammatory and microbiome alterations that may occur with xylitol exposure compared with placebo. The investigators hypothesize that pregnant individuals who chew xylitol-containing chewing gum will have a significant reduction in periodontal disease metrics at 28-30 weeks' gestation (e.g. bleeding on probing) as well as offspring with improved neurodevelopmental outcomes as assessed by the Bayley Scales of Infant and Toddler Development 4th edition and reduced risk of adverse pregnancy outcomes including preterm birth.",[28,29,30,31,32],"Preterm Birth","Low Birthweight Neonate","Periodontitis","Gingivitis","Developmental Delay",[34,35,36,37,38,39,40],"xylitol","preterm birth","prematurity","pregnancy","periodontitis","periodontal disease","chewing gum","RECRUITING","2026-08-18",{"date":44,"type":45},"2026-08-20","ACTUAL",{"date":47,"type":45},"2026-03-26",{"date":49,"type":21},"2030-09-30",{"name":51,"class":52},"University of Washington","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100652440","occlusal-force-and-chewing-after-periodontal-therapy-100652440","NCT07772115","Occlusal Force and Chewing After Periodontal Therapy","Digital Assessment of Occlusal Force Distribution and Chewing Cycles Before and After Periodontal Therapy in Patients With Stage III-IV Periodontitis","Inclusion Criteria:\n\n1. Adults aged 18-70 years.\n2. Diagnosis of Stage III or Stage IV periodontitis (Grade A, B, or C) according to the 2018 World Workshop Classification.\n3. Presence of at least 20 natural teeth, including posterior occlusal support.\n4. No periodontal treatment within the preceding 12 months.\n5. Willing and able to attend all scheduled follow-up appointments\n\nExclusion Criteria:\n\n1. Systemic conditions known to impair periodontal healing, including:\n\n   * Uncontrolled diabetes mellitus (HbA1c \\>7%)\n   * Immunosuppressive therapy\n   * Bisphosphonate therapy\n2. Removable prostheses replacing multiple posterior teeth.\n3. Pregnancy or breastfeeding.\n4. Current occlusal splint wearers.\n5. Planned dental treatment other than periodontal therapy during the study period.\n6. Heavy smokers (\\>20 cigarettes\u002Fday).\n7. Stage I or Stage II periodontitis, gingivitis, or a healthy periodontium.\n8. Severe manual dexterity impairment preventing adequate oral hygiene.\n9. Currently undergoing periodontal treatment.","ALL","18 Years","70 Years",{"count":65,"type":21},30,[67],"NA","Stage III and Stage IV periodontitis are associated with loss of periodontal support, tooth mobility, and impaired oral function, which may affect occlusal force distribution and chewing performance. Although non-surgical periodontal therapy effectively improves periodontal health, its effect on functional occlusal parameters and mandibular movements has not been comprehensively evaluated using digital technologies.\n\nThis prospective interventional study will investigate changes in occlusal force distribution and chewing cycle characteristics in patients with Stage III or Stage IV periodontitis before and after non-surgical periodontal therapy. Participants will receive standardized periodontal treatment and will be assessed at baseline, 8-12 weeks after completion of active therapy, and 3 months following re-evaluation. The T-Scan digital occlusal analysis system will be used to record occlusal force distribution, occlusion time, disocclusion time, and force balance. The Modjaw jaw-tracking system will be used to look at chewing cycle characteristics and mandibular movements. The study aims to determine whether periodontal therapy leads to measurable improvements in oral function and to provide objective functional outcome measures that may support periodontal and prosthodontic treatment planning.",[30],"NOT_YET_RECRUITING","2026-08-17",{"date":73,"type":45},"2026-08-19",{"date":75,"type":21},"2026-10-06",{"date":77,"type":21},"2028-02-01",{"name":79,"class":52},"Mohammed Bin Rashid University of Medicine and Health Sciences",{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":61,"minAge":62,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":53},"100652592","boron-levels-oxidative-stress-and-inflammation-in-periodontitis-100652592","NCT07775378","Boron Levels, Oxidative Stress, and Inflammation in Periodontitis","Evaluation of the Relationship Between Boron Levels and Oxidative Stress, Antioxidant Defense, and Inflammatory Markers in Individuals With Periodontitis","Inclusion Criteria:\n\n* Volunteering to participate in the study and signing the informed consent form\n* Being between 18 and 65 years of age\n* Being systemically healthy\n* No antibiotic use within the last 3 months\n* No periodontal treatment within the last 6 months\n* Being a non-smoker or having quit smoking at least 5 years ago\n* Not being pregnant or breastfeeding\n* No current use of steroids, immunosuppressive drugs, or non-steroidal anti-inflammatory drugs\n* No current use of medications associated with gingival enlargement, such as calcium channel blockers, phenytoin, or cyclosporine\n* No regular use of boron-containing supplements or multivitamin complexes\n* For the periodontally healthy group: no clinical attachment loss, bleeding on probing \\\u003C10%, probing depth ≤3 mm, no radiographic bone loss, and an indication for crown-lengthening surgery\n* For the periodontitis group: diagnosis of Stage III or IV periodontitis according to the 2017 World Workshop classification and an indication for periodontal flap surgery\n\nExclusion Criteria:\n\n* Incomplete or unreliable clinical measurements\n* Insufficient saliva or gingival tissue sample for biochemical analyses\n* Regular use of boron-containing oral care products within the last 3 months\n* Regular consumption of boron-rich supplements or mineral waters\n* Failure to comply with the study protocol",true,"65 Years",{"count":90,"type":21},60,"OBSERVATIONAL","This cross-sectional observational study aims to evaluate the relationship between boron levels and oxidative stress, antioxidant defense, and inflammatory markers in individuals with periodontitis. The study will include systemically healthy, non-smoking individuals divided into two groups: periodontally healthy controls and patients with Stage III-IV periodontitis. Boron levels and selected oxidative stress, antioxidant, and inflammatory biomarkers will be evaluated in saliva and gingival tissue samples. The findings will be compared between the groups to investigate the potential relationship between boron levels and periodontal inflammation and oxidative stress.",[30],[95,96,97,98,99,100],"Boron","Oxidative Stress","Antioxidant Defense","Inflammation","Saliva","Gingival Tissue","2026-08-16",{"date":44,"type":45},{"date":104,"type":45},"2026-02-26",{"date":106,"type":21},"2027-03",{"name":108,"class":52},"Marmara University",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":88,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":53},"100637561","hyaluronic-acid-as-an-adjunct-to-non-surgical-periodontal-therapy-in-smokers-100637561","NCT07597213","Hyaluronic Acid as an Adjunct to Non-Surgical Periodontal Therapy in Smokers","The Effect of Adjunctive Use of Hyaluronic Acid in Non-Surgical Periodontal Treatment in Smoking Patients","Inclusion Criteria:\n\n1. Individuals who sign the informed consent form\n2. Participants who are systemically healthy\n3. Participants who smoke (for \\>5 years and ≥10 cigarettes per day)\n4. Participants diagnosed with Stage III or Stage IV periodontitis\n5. Participants with at least 20 natural teeth present in the mouth (excluding third molars)\n6. Participants with two non-adjacent interproximal sites in each quadrant of either jaw, presenting probing depth (PD) and clinical attachment level (CAL) ≥6 mm, and with no caries, restorations, or furcation involvement\n\nExclusion Criteria:\n\n1. Individuals who do not sign the informed consent form\n2. Individuals having any systemic disease\n3. Participants who have used antibiotics within the last 3 months\n4. Participants who have received any periodontal treatment within 6 months prior to the study\n5. Participants who are pregnant or lactating",{"count":117,"type":21},23,[67],"The goal of this clinical trial is to evaluate whether hyaluronic acid (HA) improves periodontal healing in people with periodontal disease who smoke. Moreover, the effects of HA on biomolecules and bacteria levels will be assessed during the follow up period.\n\nThe main questions it will answer are:\n\nWill periodontal sites treated with HA gel after non-surgical periodontal treatment (NSPT) lead to better outcomes in clinical parameters compared to the sites treated with NSPT only in smokers?\n\nWill adjunctive use of HA gel reduce oxidative stress markers and bacteria levels during follow-up?\n\nResearchers will compare periodontal sites receiving NSPT with adjunctive HA gel application to sites receiving NSPT alone to determine whether HA provides additional clinical, biochemical and microbiological benefits.\n\nParticipants will:\n\n* first receive full-mouth NSPT then, randomization will be performed in selected jaw to determine the test sites. These two interproximal test sites will additionally receive HA gel application.\n* attend follow-up visits at 1, 3 and 6 months for clinical periodontal measurements and to provide gingival crevicular fluid samples (GCF) and subgingival samples.\n\nThe GCF samples will be evaluated for Metallothionein (MT) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and subgingival samples for periodontal pathogens.",[121,122,123,96,124,125,30],"Hyaluronic Acid","Periodontal Therapy","Oral Microbiota","Metallothionein","8-OHdG",[127,38,128,129,125,130,131],"hyaluronic acid","periodontal pathogens","metallothionein","Non-surgical periodontal treatment","split-mouth study",{"date":42,"type":45},{"date":134,"type":45},"2026-07-13",{"date":136,"type":21},"2028-07",{"name":108,"class":52},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":53},"100652214","morphological-characteristics-of-mandibular-molar-furcation-involvement-and-efficacy-of-regenerative-surgical-treatment-100652214","NCT07770256","Morphological Characteristics of Mandibular Molar Furcation Involvement and Efficacy of Regenerative Surgical Treatment","Morphological Characteristics of Furcation Involvement in Mandibular Molars and Efficacy of Regenerative Surgical Treatment: A Cross-Sectional and Interventional Trial","Inclusion Criteria:\n\n* Patients aged 18 years or older who signed the informed consent form.\n* Diagnosed with Stage III or Stage IV periodontitis according to the 2017 AAP\u002FEFP classification.\n* Completed non-surgical periodontal therapy with full-mouth plaque score (FMPS) and bleeding on probing (FMBS) \\\u003C= 20%.\n* Presence of at least one mandibular molar with Hamp Class II furcation involvement (horizontal bone loss \\> 3 mm without through-and-through communication).\n* Target tooth requirements:\n\n  * Probing pocket depth (PPD) \\>= 5 mm.\n  * Clinical attachment loss (CAL) \\>= 3 mm.\n  * Tooth mobility \\\u003C= Grade I (Miller index).\n  * Vital pulp or adequately filled root canal treatment without periapical radiolucency.\n  * Gingival margin positioned coronal to the furcation entrance.\n  * Intact tooth structure without root fractures or furcation caries.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases (e.g., uncontrolled diabetes, hypertension, cardiovascular disease, severe osteoporosis).\n* Pregnant or lactating women.\n* Current smokers or individuals who quit smoking less than 6 months prior to enrollment.\n* Use of antibiotics, anti-inflammatory agents, or medications affecting bone metabolism (e.g., bisphosphonates, high-dose corticosteroids, anti-resorptive drugs) within the past 3 months.\n* Previous periodontal surgery at the evaluation site within the past 6 months.\n* Target teeth presenting with:\n\n  * Miller Grade II or Grade III tooth mobility.\n  * Severe bone destruction extending to the root apex.\n  * Metallic restorations (metal crowns, amalgam fillings, or large metallic posts) causing significant scatter\u002Fartifacts on CBCT scans.\n  * Fused roots or abnormal root anatomy.",{"count":146,"type":21},98,[67],"This study consists of two components evaluating furcation involvement in mandibular molars among Stage III or Stage IV periodontitis patients. Component 1 is a cross-sectional study evaluating the prevalence and morphological characteristics of Hamp Class II furcation defects during initial screening. Component 2 is a randomized controlled clinical trial in 30 selected patients comparing the diagnostic accuracy of Cone Beam Computed Tomography (CBCT) against direct intra-operative clinical measurements, as well as evaluating the clinical and radiographic outcomes of regenerative periodontal surgery using Acellular Dermal Matrix (ADM) + Enamel Matrix Derivative (EMD) + Xenograft versus Autogenous Connective Tissue Graft (CTG) + EMD + Xenograft.",[30,150,151],"Periodontitis (Stage 3)","Furcation Defects",[153,154,155,156,157],"Periodontal Regeneration","Connective Tissue Graft","Enamel Matrix Derivative","Acellular Dermal Matrix","Cone-Beam Computed Tomography","2026-08-14",{"date":42,"type":45},{"date":161,"type":45},"2026-05-02",{"date":163,"type":21},"2028-05",{"name":165,"class":52},"University of Medicine and Pharmacy at Ho Chi Minh City",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":53},"100650485","caffeine-intake-and-periodontal-treatment-outcomes-100650485","NCT07747545","Caffeine Intake and Periodontal Treatment Outcomes","Effects of Dietary Caffeine Intake on Periodontal Treatment Outcomes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 55 years.\n* Diagnosed with periodontitis according to the 2018 Classification of Periodontal and Peri-Implant Diseases and Conditions.\n* First visit for periodontal treatment and eligible for standard non-surgical periodontal therapy.\n* Willing and able to comply with the dietary intervention and scheduled follow-up visits.\n* Able to understand the study procedures and provide written informed consent.\n* Able to communicate effectively and complete study questionnaires and follow-up assessments.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n* History of periodontal treatment within the previous 6 months.\n* Current smokers or tobacco users.\n* Use of antibiotics, anti-inflammatory drugs, immunosuppressive agents, or medications known to affect periodontal status within the previous 3 months.\n* Presence of systemic diseases that may influence periodontal conditions, including diabetes mellitus, hypertension, or hyperlipidemia.\n* Severe systemic diseases, psychiatric disorders, or other conditions that may interfere with study participation or protocol compliance.\n* Allergy or intolerance to caffeine or inability to comply with the dietary caffeine intervention.\n* Individuals with limited hand function or other conditions preventing adequate oral hygiene practices.","55 Years",{"count":175,"type":21},90,[67],"This study will explore whether caffeine intake can affect recovery after periodontal (gum) treatment.\n\nPeriodontitis is a common gum disease caused by bacteria. Even after treatment, some people may still have ongoing inflammation or changes in oral bacteria. Researchers want to know if daily caffeine intake, such as from coffee, may help improve this condition.\n\nIn this study, about 90 adults with periodontitis will receive standard periodontal treatment. Participants will be randomly assigned to one of three groups: no caffeine intake, low caffeine intake, or moderate caffeine intake. They will follow these instructions for about 6 months.\n\nResearchers will collect saliva samples and check gum health at several time points after treatment. Saliva will be used to measure inflammation markers and to study changes in oral bacteria. Researchers will also record clinical gum conditions, such as gum pocket depth and bleeding.\n\nThe goal of this study is to understand whether caffeine intake can help reduce inflammation, improve oral bacteria balance, and support recovery after periodontal treatment. The results may help provide simple dietary advice to improve long-term gum health.",[30],[180,181,182,183,184,185,30],"Dietary caffeine","Caffeine intake","Non-surgical periodontal therapy","Oral microbiome","Salivary inflammatory biomarkers","Randomized controlled trial",{"date":42,"type":45},{"date":188,"type":21},"2026-08-01",{"date":190,"type":21},"2027-12-31",{"name":192,"class":52},"Haoran Feng",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":53},"100651706","efficacy-of-prf-and-xenograft-in-treating-mandibular-molar-furcation-involvements-100651706","NCT07764029","Efficacy of PRF and Xenograft in Treating Mandibular Molar Furcation Involvements","Efficacy of Platelet-Rich Fibrin Combined With Xenograft in the Treatment of Mandibular Molar Furcation Involvements","Inclusion Criteria:\n\n* Patients over 18 years old\n* Patients diagnosed with periodontitis who have completed non-surgical treatment: scaling and root planing\n* Patients attending a follow-up visit at least 5 weeks after non-surgical treatment, demonstrating compliance and good oral hygiene cooperation\n* Presence of a mandibular molar with a Degree II furcation involvement according to Hamp (1975), presenting a residual periodontal pocket at the buccal site (PPD ≥ 5mm) after non-surgical treatment, and showing radiolucency in the furcation area on CBCT imaging\n* Plaque Index (PlI) \\\u003C 1 following non-surgical treatment\n* Width of keratinized gingiva ≥ 2mm\n* Teeth with furcation defects where gingival recession does not extend apically beyond the buccal furcation fornix (no supragingival furcation exposure)\n* Teeth without occlusal trauma, pulpal or periapical pathologies, and no combined periodontic-endodontic lesions\n* Degree II furcation involvement according to Hamp (1975) and Subclass A or B according to Tarnow and Fletcher (1984)\n* The defect is located apical to the interproximal alveolar bone crest on CBCT imaging\n\nExclusion Criteria:\n\n* Patients with systemic diseases affecting periodontal treatment outcomes, such as: diabetes mellitus, heart disease requiring anticoagulant therapy, blood disorders, immunodeficiency, etc\n* Pregnant or lactating patients\n* Patients who have used antibiotics or any other medications affecting periodontal treatment outcomes within the last 6 months\n* Patients who smoke tobacco.\n* Patients who have used aspirin or medications affecting blood coagulation within 2 weeks prior to the blood collection for PRF preparation\n* Patients with a history of allergy to local anesthetics\n* Defects associated with grade II tooth mobility that has not been splinted, or grade III tooth mobility according to Miller (2014)",{"count":201,"type":21},22,[67],"The purpose of this randomized controlled clinical trial is to compare the effectiveness of advanced platelet-rich fibrin (A-PRF+) combined with xenograft versus a collagen membrane combined with xenograft in the treatment of degree II furcation involvements in mandibular first molars. Adult patients with periodontitis will randomly receive either the A-PRF+ treatment or the collagen membrane treatment during periodontal flap surgery. The study will evaluate clinical periodontal healing, bone regeneration using 3D imaging (CBCT), patient comfort (pain levels and satisfaction), and changes in the TWEAK biomarker in gingival crevicular fluid over a 6-month period.",[30,151],[206,207,208,209,210,211,212,213],"A-PRF plus","A-PRF+","Xenograft","Mandibular Molar","Guided Tissue Regeneration","TWEAK","biomarker","collagen membrane","2026-08-12",{"date":158,"type":45},{"date":217,"type":45},"2026-06-25",{"date":219,"type":21},"2027-06-30",{"name":165,"class":52},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":246,"locationsCount":53},"100651011","minimally-invasive-non-surgical-periodontal-treatment-100651011","NCT07755644","Minimally Invasive Non-Surgical Periodontal Treatment","The Clinical Effects of Minimally Invasive NonSurgical Therapy (MINST) as an Alternative of Conventional NonSurgical Periodontal Therapy for Stage III Grade C Periodontitis in Molar Teeth- A 6-month Pilot Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 35 years.\n* Diagnosed with Stage III or Stage IV periodontitis.\n* Systemically healthy.\n* Presence of at least two bilateral molar teeth with probing pocket depth (PPD) ≥5 mm and bleeding on probing (BOP).\n* At least 20 remaining teeth.\n* Radiographic evidence of periodontal bone loss.\n* Non-smokers and non-users of tobacco or alcohol.\n* Not pregnant or breastfeeding.\n* Not receiving medications known to affect periodontal healing.\n* Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria.\n* Pregnancy or breastfeeding.\n* Presence of systemic diseases or medical conditions affecting periodontal status or healing.\n* Current use of medications that may influence periodontal healing.\n* Current smokers or users of tobacco or alcohol.\n* Individuals unwilling or unable to provide informed consent.","35 Years",{"count":117,"type":21},[67],"This single-center, split-mouth, randomized controlled clinical trial aims to evaluate the clinical effectiveness of Minimally Invasive Non-Surgical Therapy (MINST) as an adjunct to conventional non-surgical periodontal therapy in patients with Stage III\u002FIV periodontitis. Twenty-three systemically healthy adults presenting with bilateral molar teeth exhibiting periodontal pockets ≥5 mm with bleeding on probing will be enrolled. In each participant, molar teeth will be randomly allocated to receive either conventional subgingival scaling and root planing (SRP) using ultrasonic instruments alone (control) or conventional SRP followed by MINST using Mini-Five Gracey curettes under magnification loupes (test). Clinical periodontal parameters, including Plaque Index (PI), Gingival Index (GI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), will be evaluated at baseline, 3 months, and 6 months after treatment. The study will investigate whether MINST provides superior clinical outcomes compared with conventional non-surgical periodontal therapy.",[30,150],[30,234,235,236,237,238,239],"Stage III Periodontitis","Stage IV Periodontitis","Minimally Invasive Non-Surgical Therapy","MINST","Scaling and Root Planing","Root Debridement","2026-08-05",{"date":242,"type":45},"2026-08-10",{"date":188,"type":21},{"date":245,"type":21},"2027-01",{"name":247,"class":52},"Ataturk University",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":87,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":255,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":53},"100649853","periodontitis-on-gingival-crevicular-fluid-metobolomics-100649853","NCT07739732","Periodontitis on Gingival Crevicular Fluid Metobolomics","Impact of Periodontitis on Metabolomics in Gingival Crevicular Fluid","Inclusion Criteria:\n\n1. Age between 18 and 70 years.\n2. Ability to understand the study procedures and provide written informed consent.\n3. For the periodontitis group: diagnosis of periodontitis according to the 2018 classification of periodontal diseases.\n4. For the healthy control group: periodontal health according to the 2018 classification, with no current diagnosis or history of periodontitis.\n\nExclusion Criteria:\n\n1. Periodontal treatment during the previous 6 months.\n2. Use of antibiotics, non-steroidal anti-inflammatory drugs, or immunosuppressive agents during the previous 6 months.\n3. Pregnancy.",{"count":90,"type":21},"This cross-sectional observational study will compare the gingival crevicular fluid metabolomic profile of 30 adults with periodontitis and 30 periodontally healthy adults. Participants will undergo a periodontal examination and gingival crevicular fluid collection during a single study visit. Targeted metabolomic analysis will be used to identify differences between the two groups and associations with periodontal clinical parameters.",[30],"2026-07-28",{"date":260,"type":45},"2026-07-31",{"date":262,"type":45},"2026-05-04",{"date":264,"type":21},"2026-12-18",{"name":266,"class":52},"University of Catania",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":280,"leadSponsor":281,"locationsCount":53},"100649810","impact-of-non-surgical-periodontal-treatment-on-targeted-metabolomics-100649810","NCT07740447","Impact of Non-surgical Periodontal Treatment on Targeted Metabolomics","Effects of Minimally Non-surgical Periodontal Treatment Versus Quadrantwise Subgingival Instrumentations on Targeted Metabolomics in Gingival Crevicular Fluid","Inclusion Criteria:\n\n* Diagnosis of Periodontitis\n\nExclusion Criteria:\n\n* Periodontal treatment during the last 6 months\n* Use of antibiotics, NSAIDs, and immunosuppressants during the last 6 months\n* Pregnancy",{"count":90,"type":21},[67],"A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment by means of minimally invasive approach MINST or Q-SI (quadrantwise) approach in subjects with periodontitis on targeted metabolomics in gingival crevicular fluid",[30],{"date":260,"type":45},{"date":262,"type":45},{"date":264,"type":21},{"name":266,"class":52},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":61,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":311,"locationsCount":53},"100648809","adjunctive-subgingival-pomegranate-peel-extract-gel-for-stage-ii-iii-periodontitis-100648809","NCT07725393","Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis","Adjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis: A Randomized Split-Mouth Trial","POME-PERIO","Inclusion Criteria:\n\n* Adults aged 30 to 60 years.\n* Systemically healthy individuals.\n* Diagnosis of Stage II or Stage III periodontitis according to the 2018 Classification of Periodontal and Peri-Implant Diseases and Conditions.\n* Presence of at least 20 natural teeth.\n* Presence of at least two non-adjacent periodontal pockets (≥5 mm) located in different quadrants suitable for split-mouth allocation.\n* Clinical attachment loss consistent with Stage II or Stage III periodontitis.\n* Ability and willingness to comply with the study protocol and attend all follow-up visits.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Current smokers or users of any tobacco products.\n* Pregnant or lactating women.\n* Patients with systemic diseases known to affect periodontal status or wound healing (e.g., uncontrolled diabetes mellitus, immunodeficiency disorders, osteoporosis requiring antiresorptive therapy).\n* Use of systemic antibiotics, corticosteroids, immunosuppressive agents, or non-steroidal anti-inflammatory drugs within the previous 3 months.\n* Periodontal therapy received within the previous 6 months.\n* History of allergy or hypersensitivity to pomegranate or any component of the study materials.\n* Orthodontic treatment during the study period.\n* Participation in another clinical trial within the previous 6 months.","30 Years","60 Years",{"count":293,"type":21},32,[67],"This randomized, triple-blind, placebo-controlled split-mouth clinical trial aims to evaluate the clinical and biochemical efficacy of subgingival pomegranate peel extract gel as an adjunct to scaling and root planing (SRP) in the treatment of Stage II-III periodontitis.\n\nThirty-two participants diagnosed with Stage II-III periodontitis will receive SRP in all selected periodontal sites. Test sites will receive locally delivered pomegranate peel extract gel, while contralateral control sites will receive a placebo gel. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), bleeding on probing (BOP), and gingival crevicular fluid levels of matrix metalloproteinase-8 (MMP-8), will be assessed at baseline, 1 month, 3 months, and 6 months to evaluate whether adjunctive pomegranate peel extract gel improves periodontal healing compared with SRP alone.",[30],[298,299,300,301,302,303,304],"Stage II periodontitis","Stage III periodontitis","Scaling and root planing","Pomegranate peel extract","Local drug delivery","Split-mouth trial","Randomized clinical trial","2026-07-21",{"date":307,"type":45},"2026-07-24",{"date":309,"type":45},"2026-07-01",{"date":245,"type":21},{"name":312,"class":52},"gehad samy",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":53},"100630069","tinder-fungus-as-an-adjunct-to-non-surgical-periodontal-therapy-for-periodontitis-100630069","NCT07482878","Tinder Fungus as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis","Tinder Fungus (Fomes Fomentarius) as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients diagnosed with Stage III or IV periodontitis\n* Patients who have not yet initiated periodontal therapy\n* Patients who have at least 20 remaining teeth\n* Patients who are willing to use an electric toothbrush\n* Patients who are willing to use interdental brushes\n\nExclusion Criteria:\n\n* Patients who have previously received treatment for periodontitis\n* Patients who have already undergone or initiated periodontal therapy\n* Patients with a known allergy or intolerance to any component of the toothpaste or the powder\n* Patients who are already using a product that contains tinder fungus (Fomes fomentarius)\n* Patients who, at the time of periodontal treatment, are undergoing active systemic cancer therapy (e.g., chemotherapy or immunotherapy) or radiotherapy in the head and neck region, or for whom such therapy is planned. Previous illnesses or completed therapies do not constitute an exclusion criterion, provided that no current or planned treatment exists that could influence the periodontal treatment outcome or pose an increased risk for the participants.",{"count":321,"type":21},70,[67],"The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.\n\nThe main questions it aims to answer is:\n\n• Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.\n\nParticipants will:\n\n* Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days\n* Visit the clinic at least twice including a visit before and after the intervention\n* Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.",[30],"2026-07-14",{"date":327,"type":45},"2026-07-16",{"date":329,"type":21},"2026-09",{"date":331,"type":21},"2028-12",{"name":333,"class":52},"Sigmund Freud PrivatUniversitat",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":343,"briefSummary":345,"conditions":346,"keywords":350,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":53},"100647362","phase-4-this-a-clinical-trial-to-evaluate-the-efficacy-of-i-prf-povidone-iodine-and-laser-as-adjuncts-to-non-surgical-periodontal-treatment-in-smokers-and-non-smokers-periodontitis-patients-100647362","NCT07707063","This a Clinical Trial to Evaluate the Efficacy of I-PRF, Povidone-Iodine and Laser as Adjuncts to Non-surgical Periodontal Treatment in Smokers and Non-Smokers Periodontitis Patients","Clinical Efficacy of I-PRF, Povidone-Iodine and Laser as Adjuncts to Non-surgical Periodontal Treatment in Smokers and Non-Smokers Periodontitis Patients : A Split Mouth Randomized Clinical Trial","Inclusion: Patients with Stage II-IV Periodontitis; at least one bleeding pocket \\> 4 mm minimum in every quadrant.\n\nExclusion: patients who:\n\n* Pregnant \u002FLactating\n* History of radiotherapy or chemotherapy in the head\u002Fneck region.\n* Known hypersensitivity to Iodine or Methylene blue solution\n* Systematic antibiotic use within the last 30 days\n* Long-term use of immunosuppressants or corticosteroids (daily use)\n* type 1 \u002F 2 diabetes",{"count":342,"type":21},50,[344],"PHASE4","This study is a randomized, controlled, split-mouth clinical trial designed to evaluate and compare the effectiveness of four different subgingival adjuncts used along side standard Scaling and Root Planning (SRP). This protocol is designed to be a standardized therapeutic model. The subgingival adjuncts are standardized, ensuring that the results are not operator dependent and can be replicated across any dental unit. The primary goal of this study is to evaluate the clinical efficacy of three distinct adjunctive strategies: Biological (I-PRF), Antiseptic : Povidone- iodine , Diode-Laser activation, compared to a Saline Control in the initial treatment of stage 2, 3 and stage 4 of the 2018 AAP\u002FEFP periodontal classification.",[30,347,348,349],"Smokers","Non Smokers","Periodontal Disease",[351,352,353,354,355,356,357],"Injectable platelet-rich fibrin (I-PRF)","Diode Laser","iodine solution","Periodontal Pockets","periodontal debridement","lasers","Regenerative periodontal therapy","2026-07-10",{"date":327,"type":45},{"date":361,"type":45},"2026-05-25",{"date":363,"type":21},"2027-05-18",{"name":365,"class":52},"Military Hospital of Tunis",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":87,"sex":61,"minAge":62,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":388,"locationsCount":53},"100645716","salivary-apelin-chemerin-ghrelin-and-lipocalin-2-levels-in-diabetic-patients-with-periodontitis-100645716","NCT07703345","Salivary Apelin, Chemerin, Ghrelin, and Lipocalin-2 Levels in Diabetic Patients With Periodontitis","Evaluation of Salivary Apelin, Chemerin, Ghrelin and Lipocalin 2 Levels in Diabetic Patients With Periodontitis","Inclusion Criteria:\n\n* Individuals aged 18 to 80 years. Individuals who apply to the Department of Periodontology, Faculty of Dentistry, Necmettin Erbakan University.\n\nIndividuals who agree to participate in the study and sign the informed consent form.\n\nPresence of at least 20 teeth. For the periodontally healthy groups: diagnosis of periodontal health based on routine clinical and radiographic examination.\n\nFor the periodontitis groups: diagnosis of generalized Stage II or Stage III periodontitis based on routine clinical and radiographic examination according to the 2017 World Workshop Classification of Periodontal and Peri-Implant Diseases and Conditions.\n\nFor the type 2 diabetes mellitus groups: diagnosis of type 2 diabetes mellitus. For the systemically healthy groups: absence of systemic diseases, including type 2 diabetes mellitus.\n\nExclusion Criteria:\n\n* Periodontal treatment, including scaling and root surface debridement, within the last 6 months.\n\nAntibiotic use within the last 6 months. Pregnancy or lactation. Presence of autoimmune diseases such as rheumatoid arthritis, familial Mediterranean fever, ankylosing spondylitis, Behçet disease, or psoriasis.\n\nPresence of systemic diseases other than type 2 diabetes mellitus in the diabetes groups.\n\nPresence of systemic diseases such as nephrotic syndrome, chronic renal disease, or cardiovascular disease.\n\nSmoking 10 or more cigarettes per day.","80 Years",{"count":375,"type":21},88,"This observational cross-sectional study will evaluate salivary apelin, chemerin, ghrelin, and lipocalin-2 levels in individuals with different periodontal and systemic conditions. Participants will be divided into four groups according to periodontal status and the presence or absence of type 2 diabetes mellitus.\n\nClinical periodontal measurements and unstimulated saliva samples will be obtained before periodontal treatment. Salivary biomarker levels will be measured using enzyme-linked immunosorbent assay kits. The study aims to determine whether salivary apelin, chemerin, ghrelin, and lipocalin-2 levels are associated with periodontitis, type 2 diabetes mellitus, and periodontal clinical parameters.",[30,378],"Type 2 Diabetes Mellitus (T2DM)",[30,380,381,382,383],"Type 2 Diabetes Mellitus","Salivary Biomarkers","Apelin","Chemerin","2026-07-09",{"date":325,"type":45},{"date":309,"type":45},{"date":188,"type":21},{"name":389,"class":52},"Necmettin Erbakan University",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":87,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":53},"100646510","short-implants-in-unitary-implant-supported-rehabilitations-in-the-posterior-maxilla-and-mandible-5-years-of-follow-up-100646510","NCT07688408","Short Implants in Unitary Implant-supported Rehabilitations in the Posterior Maxilla and Mandible: 5 Years of Follow-up","Short Implants (7 and 8 mm) in Unitary Implant-supported Rehabilitations in the Posterior Sector of the Maxilla and Mandible: 5 Years of Follow-up","Inclusion Criteria:\n\n* Individuals (\\> 21 years old), of both sexes, specifically rehabilitated with morse connection implants (Implacil De Bortoli, São Paulo, SP, Brazil) in the posterior region of the jaws for single-sided unsupported restorations, will be included in this study. Individuals will also need to have at least initial radiographic controls (immediately after implant placement) and 12 and 60 months of follow-up after implant placement. Individuals will be included in the population sample, with the following criteria observed: location, implant installation region, implant diameter, and adaptation.\n\nExclusion Criteria:\n\n* Immediate implants will be excluded, individuals with clinical records who, throughout the study, do not have radiographs for evaluation and\u002For radiographs of poor quality that make radiographic measurements impossible; medical records with insufficient data, filled out inappropriately or that indicate doubt about the details of the procedure performed.",{"count":398,"type":21},100,"Implant-supported rehabilitation of regions with severe bone resorption is a challenge for implant dentists. Structures such as the maxillary sinus and the inferior alveolar canal often make it impossible to use implants of lengths considered standard in the literature. The use of short 7 and 8 mm implants with new macrogeometries and surface treatments, in addition to the application of Morse taper prosthetic connections, has shown results that increasingly encourage their use. However, the longevity of these rehabilitations needs to be constantly evaluated. In this work, unitary implant-supported rehabilitations in the posterior jaws, supported by short (7 and 8 mm) tapered Morse connection implants, will be followed for a period of 5 years. A total of 100 subjects rehabilitated with tapered Morse connection implants, with diameters between 3.5 and 4.5 mm, will be evaluated. Peri-implant bone remodeling, implant stability measured through ISQ and clinical parameters will be evaluated per implant and over the evaluation time. Periapical radiographs will be obtained and digitized, analyzed by software and compared with the initial data. The data obtained will be analyzed, allowing longitudinal evaluations and the success rate of implant restorations supported by short implants.",[30,349],"2026-07-06",{"date":403,"type":45},"2026-07-08",{"date":405,"type":21},"2026-06-28",{"date":407,"type":21},"2027-02-28",{"name":409,"class":52},"University of Guarulhos",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":53},"100644263","evaluation-of-masticatory-performance-in-patients-with-periodontitis-100644263","NCT07665489","Evaluation of Masticatory Performance in Patients With Periodontitis","PAROCHEW","Inclusion Criteria:\n\n* Patients followed at the university hospital (CHU) with a diagnosis of periodontitis.\n* No objection from the patient to participate in the study.\n* Patients able to speak and understand French.\n\nExclusion Criteria:\n\n* Minors.\n* Patients under legal protection (guardianship, trusteeship, or judicial protection measures).\n* Pregnant or breastfeeding women.\n* Patients who refuse to participate in the study.",{"count":398,"type":21},"The objective of this observational study is to assess the correlation between the severity of periodontal involvement and masticatory performance in patients with periodontitis.\n\nThe secondary objectives are to identify periodontal parameters that may be associated with a reduction in masticatory performance.\n\nThis study includes a single group.\n\nParticipants will be asked to perform a masticatory performance test consisting of chewing a piece of gum for 20 cycles.",[420,30,421],"Periodontitis, Adult","Oral Disease","2026-07-02",{"date":401,"type":45},{"date":425,"type":21},"2026-09-01",{"date":427,"type":21},"2027-09-01",{"name":429,"class":52},"University Hospital, Clermont-Ferrand",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":448,"locationsCount":53},"100642636","evaluation-of-the-impact-of-periodontitis-and-its-treatment-on-swallowing-functions-and-oral-quality-of-life-100642636","NCT07651579","Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life","FI-PAROCROC","Inclusion Criteria:\n\n* Patients treated at the university hospital and diagnosed with periodontitis\n* Adult patients who have provided informed consent\n* Patients enrolled in a social security system\n* Patients who speak and understand French.\n\nExclusion Criteria:\n\n* Minors\n* Pregnant or breastfeeding patients\n* Patients under legal protection or conservatorship\n* Patients who refuse to participate in the study",{"count":438,"type":21},44,[67],"The objective of this single-center prospective study is to evaluate the impact of periodontal treatment on masticatory performance in patients with periodontitis.\n\nParticipants will be asked to complete several questionnaires related to their oral health and quality of life. Functional masticatory tests and salivary flow measurements will also be performed.",[30,442,443],"Periodontal Diseases","Quality of Life",{"date":401,"type":45},{"date":425,"type":21},{"date":447,"type":21},"2028-09-01",{"name":429,"class":52},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":87,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":53},"100593995","prf-as-adjunct-to-subgingival-instrumentation-in-step-2-periodontal-therapy-100593995","NCT07013682","PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy","Platelet Rich Fibrin Adjunctive to Non-surgical Periodontal Therapy: a 6-month Split-mouth Randomized Controlled Clinical Trial","PRFSTEP2","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Periodontitis stage II-IV, grade A\u002FB\u002FC, generalized\n* Presence of at least 20 teeth (excluding wisdom teeth)\n* Absence of removable dentures\n* Patients willing to provide written informed consent and to complete the 6- month study follow-up\n\nExclusion Criteria:\n\n* Patients already participating in other clinical trials\n* Periodontal treatment in the previous 12 months\n* Antibiotic treatment 3 months prior to study entry\n* Antibiotic prophylaxis required for dental treatment\n* Current use of any medication that may affect the clinical features of periodontitis\n* Pregnant\u002Flactating\n* Any condition that prevents venipuncture\n* Not willing to venous puncture\n* Current cancer treatment\n* History of radiation in the head-neck area",{"count":458,"type":21},20,[67],"Periodontitis is characterized by a chronic, multifactorial inflammatory process driven by dysbiotic plaque biofilms. It is recognized as the most common chronic inflammatory non-communicable disease in humans. The advanced and severe forms of periodontitis have an estimated prevalence of 7.4%, while milder forms can affect up to 50% of the population.\n\nIf left untreated, periodontitis can lead to tooth loss. However, it is largely preventable and treatable with mechanical non-surgical periodontal therapy. To improve periodontal healing and thus clinical attachment gain after non-surgical therapy, adjunctive bioactive formulations such as enamel matrix derivatives, sodium hypochlorite, locally delivered antimicrobials, or hyaluronic acid have recently been proposed. However, these agents are non-autologous formulations and expensive.\n\nPlatelet-rich fibrin (PRF) acts as a scaffold that inhibits the early migration of epithelial cells into the periodontal tissues. Its regenerative properties are primarily due to its ability to promote angiogenesis. This ability is attributed to the 3D fibrin matrix, which can simultaneously transport several cytokines and growth factors. These include vascular endothelial growth factor (VEGF), insulin growth factor (IGF), transforming growth factor β1 (TGF-β1) and platelet-derived growth factor (PDGF). PRF further shows antibacterial properties and accelerates soft tissue healing. So far PRF is not routinely used in periodontal non-surgical therapy.\n\nThe aim of this 6-month, split-mouth randomized clinical trial including 20 patients is to test whether PRF can improve the results after non-surgical therapy.",[30,462,463],"Periodontal Inflammation","Periodontal Attachment Loss","2026-06-30",{"date":422,"type":45},{"date":467,"type":45},"2025-05-01",{"date":469,"type":21},"2027-12-24",{"name":471,"class":52},"University of Bern",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":87,"sex":61,"minAge":478,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":53},"100644993","breaking-the-cycle-real-time-family-oral-microbial-transmission-patterns-as-intervention-targets-100644993","NCT07674888","Breaking the Cycle: Real-Time Family Oral Microbial Transmission Patterns as Intervention Targets","Inclusion Criteria:\n\n* Families with at least two children aged 5-12 years living in the same household.\n* least one parent or guardian diagnosed with Stage II or III periodontitis requiring non-surgical periodontal therapy.\n* At least one child who has undergone caries treatment and is considered at high risk for disease recurrence.\n* Willingness of all participating household members to provide oral samples and participate in study procedures.\n* Ability of participants or their legal guardians to provide informed consent, and assent from children where applicable.\n\nExclusion Criteria:\n\n* Children living in multiple households or shared-custody arrangements during the study period.\n* Households unable to complete study visits or follow-up procedures.\n* Individuals unwilling or unable to comply with study procedures.\n* Individuals who do not provide informed consent or assent, where applicable.\n* Medical or behavioral conditions that, in the opinion of the investigators, would preclude safe participation in the study.","5 Years",{"count":480,"type":21},225,[67],"This study aims to understand how oral bacteria that cause tooth decay and gum disease spread among family members and whether treating multiple family members can reduce the return of these bacteria after dental treatment.\n\nFamilies with children aged 5-12 years will be recruited from university dental clinics. Participants will be assigned to one of three treatment groups: treatment for the child only, treatment for the child and parents, or treatment for all family members. Researchers will collect oral bacterial samples from family members before and after treatment and will monitor close-contact interactions within the household using wearable proximity-tracking devices.\n\nThe study will also collect information about oral health habits, family interactions, and environmental factors that may influence bacterial transmission. By combining bacterial DNA analysis with information about family contact patterns, researchers hope to better understand how oral bacteria are shared within households and whether family-based treatment approaches can reduce bacterial recolonization after dental therapy.\n\nThe results of this study may help improve strategies for preventing childhood tooth decay and gum disease by addressing family-level sources of bacterial transmission.",[484,30,485,486],"Dental Caries","Oral Microbiome","Bacterial Transmission",[488,183,489,490,491,492,493,494,495,496,497,498,499],"family microbial transmission","Plaque recolonization","Pediatric oral health","Real-time proximity tracking","Ultrawide Band (UWB)","Oral bacterial transmission","Intergenerational pathogen transfer","Biofilm disruption","Periodontal disease","Family-based intervention","Microbial source tracking","Oral Health",{"date":464,"type":45},{"date":502,"type":21},"2026-09-30",{"date":504,"type":21},"2028-06-30",{"name":506,"class":52},"University of Alberta",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":516,"conditions":517,"keywords":525,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":534,"locationsCount":53},"100638972","periodontal-disease-in-rare-renal-disorders-perio-ra-re-100638972","NCT07575347","Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)","Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease","PERIO-RA-RE","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* At least 10 natural teeth present\n* Belonging to one of the predefined study groups:\n\n  1. Alport syndrome (genetically or clinically confirmed)\n  2. Fabry disease (enzymatically or genetically confirmed)\n  3. Tuberous sclerosis complex (according to established clinical or genetic criteria)\n  4. Systemic lupus erythematosus defined according to the 2019 EULAR\u002FACR or SLICC 2012 classification criteria, with renal involvement defined by at least one of the following: \\[1\\] Biopsy-proven lupus nephritis, \\[2\\] Persistent proteinuria (\\>0.5 g\u002Fday or equivalent), \\[3\\] Active urinary sediment (hematuria and\u002For cellular casts) consistent with lupus nephritis\n  5. Chronic kidney disease (CKD) of non-rare etiology: defined according to KDIGO criteria (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² and\u002For markers of kidney damage)\n  6. Individuals without CKD, recruited from clinical or dental care settings as non-CKD controls\n\nExclusion Criteria:\n\n* Periodontal treatment within the last 6 months\n* Antibiotic therapy within the last 4 weeks\n* Pregnancy\n* Conditions precluding periodontal examination\n* Inability to comply with study procedures",{"count":398,"type":21},"This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.\n\nThis is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.\n\nThe primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.\n\nExploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.",[349,30,518,519,520,521,522,523,524],"CKD","Chronic Kidney Disease","Alport Syndrome","Fabry Disease","Lupus or SLE","Tuberous Sclerosis Complex (TSC)","Systemic Lupus Erythematosus (SLE)",[349,30,518,526,527,528,523,519],"Rare Kidney Diseases","Alport syndrome","Systemic Lupus Erythematosus","2026-06-24",{"date":531,"type":45},"2026-06-26",{"date":262,"type":45},{"date":190,"type":21},{"name":535,"class":52},"Stefan Lujinschi",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":4},"100644776","sterify-gel-as-an-adjunct-to-non-surgical-periodontal-therapy-in-periodontitis-100644776","NCT07672665","Sterify Gel as an Adjunct to Non-Surgical Periodontal Therapy in Periodontitis","The Adjunctive Effect of a Mucoadhesive Polymeric Hydrogel to Non-surgical Periodontal Therapy: a Retrospective Analysis","Sterify","Inclusion Criteria:\n\n* Adult patients aged \\>18 years\n* Diagnosis of stage II, III, or IV periodontitis\n* Non-smokers\n* Negative medical history\n* Patients treated with scaling and root planing\u002Fminimally invasive non-surgical periodontal therapy plus mucoadhesive polymeric hydrogel\n* Patients enrolled in supportive periodontal care\n\nExclusion Criteria:\n\n* Smokers\n* Pregnancy\n* Surgical re-treatment during the maintenance period","100 Years",{"count":458,"type":21},"This retrospective observational study will evaluate the clinical response to Sterify Gel, a sterile mucoadhesive polymeric hydrogel, when used as an adjunct to non-surgical periodontal therapy in adult patients with stage II, III, or IV periodontitis.\n\nThe study will analyze already existing anonymized clinical records from patients treated at the Periodontal Unit of IRCCS Ospedale San Raffaele in Milan, Italy. Patients included in the analysis received scaling and root planing\u002Fminimally invasive non-surgical periodontal therapy, followed by local application of Sterify Gel into periodontal pockets with probing depth greater than 4 mm.\n\nThe main objective is to assess reduction in periodontal pocket depth from baseline to 6, 12, and 24 weeks. Other periodontal clinical parameters, including clinical attachment level, gingival recession, bleeding, plaque score, tooth mobility, and furcation involvement, will also be evaluated.",[30],"2026-06-22",{"date":550,"type":45},"2026-06-29",{"date":552,"type":21},"2026-06",{"date":554,"type":21},"2026-12",{"name":556,"class":52},"IRCCS San Raffaele",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":570,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":583,"locationsCount":53},"100590437","comparative-effects-of-two-oral-antiseptics-used-as-an-adjuvant-in-the-treatment-of-periodontitis-100590437","NCT06967402","Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis","Comparative Clinical Efficacy and Microbiological Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Severe Periodontitis","Inclusion Criteria:\n\n* Consenting patients with at least 6 evaluable teeth in each quadrant, including minimum 1 molar and 1 premolar.\n* Generalized stage II-III periodontitis patients.\n* Baseline BOP \\> 25%.\n* No known allergy or adverse effects to CHX or CPC\n* Non-smokers, non-orthodontic patients, no concurrent or past antibiotics\u002Fmedication known to affect periodontal status (i.e. calcium antagonists, phenytoin)\u002Fanti-inflammatory therapy (i.e. NASIDs) in the last 3 months, pregnant\u002Fbreastfeeding, compliance to study procedures.\n* ASA class I-II patients.\n* Either non-diabetic or with controlled diabetes (HbA1C\\\u003C7).\n* Normal\u002FElevated blood pressure (AHA - Systolic \\\u003C130mmHg; Diastolic \\\u003C80mmHg).\n* No radiation\u002Fchemotherapy in the past 5 years\n* No immunosuppression including drug induced immunosuppression.\n* No participation in other clinical studies in the last 4 weeks.\n* No administration of CHX or CPC in the last 3 months\n* No periodontal treatment in the last 3 months.\n\nExclusion Criteria:\n\n* Unable to provide written consent.\n* Non-compliant study procedures.\n* Patients with medical (including psychiatric) and pharmacotherapeutic histories that, in the investigator's opinion, may compromise the protocol.\n* Patients requiring antibiotics prophylaxis for dental procedures.\n* Patients with self-reported pregnancy or patients who are breastfeeding.\n* Patients with history of use of systemic antibiotics, in combination with any form of periodontal treatment, within the past 3 months.\n* Patients with uncontrolled endocrine disease.\n* Patients who are not compliant with the review protocol, leading to deviation of more than 1 week.\n* Patients requiring the admission of systemic antibiotics, in combination with any form of dental treatment, during the study period.",{"count":90,"type":21},[67],"The focus of this study is on two types of mouthwashes - one containing a chlorhexidine (CHX) at 0.2% (CHX), and the other one containing CHX at a lower concentration of 0.12% with cetylpyridinium chloride (CPC). Both mouthwashes are used to help in the treatment of gum disease. CHX has been known for a long time for its effectiveness against plaque and mouth inflammation. It could inhibit and even kill them. However higher concentrations of CHX comes with unwanted side effect including altered taste, teeth staining and irritation in the mouth. Interestingly, these side effects seem to occur less frequently when a lower concentration CHX solution is used. CPC also combats bacteria by adhering quickly to the surfaces inside your mouth, although it has less substantivity than CHX, it has been shown to reduce plaque and gum inflammation effectively, and it typically causes fewer side effects than CHX. We hypothesize that this new formulation of CHX 0.12%+CPC mouthwash is non-inferior to CHX 0.2% in terms of its anti-plaque and anti-inflammatory properties while presenting with less side effects after 21 days of use. Microbiological samples and fluids from periodontal pockets will be collected before and after treatment for analysis of microbiological effects.",[30,568,569],"Periodontitis Stage II","Periodontitis Stage III",[571,572,573,30,574,575,576],"Mouthwash","Chlorhexidine","CPC","Mouthrinse","cetylpyridinium chloride","Oral antiseptic","2026-06-21",{"date":579,"type":45},"2026-06-23",{"date":581,"type":45},"2025-11-20",{"date":190,"type":21},{"name":584,"class":52},"The University of Hong Kong",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":61,"minAge":592,"maxAge":88,"enrollmentInfo":593,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":53},"100615049","anti-inflammatory-nutrition-on-the-outcomes-of-non-surgical-periodontal-therapy-100615049","NCT07287540","Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapy","Evaluation of the Effects of Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapy in Individuals With Periodontitis","Inclusion Criteria:\n\n* Being systemically healthy\n* Not smoking\n* Not using anti-inflammatory drugs in the last 3 months, antibiotics, or systemic corticosteroids in the last 6 months\n* Not being pregnant or lactating\n* Not having received periodontal treatment in the last 6 months\n* Having at least 20 teeth in the mouth\n* Being diagnosed with periodontitis by the investigator\n* Having a dietary inflammatory index \\>0\n\nExclusion Criteria:\n\n* Having a systemic disease\n* Smoking\n* Using anti-inflammatory drugs within the last 3 months, antibiotics within the last 6 months, or systemic corticosteroids\n* Being pregnant or lactating\n* Having received periodontal treatment within the last 6 months\n* Having fewer than 20 teeth in the mouth\n* No periodontitis","20 Years",{"count":398,"type":21},"This study aimed to determine the effect of anti-inflammatory nutrition on non-surgical periodontal treatment in individuals with periodontitis by evaluating gingival crevicular fluid (GCF) and serum biomarkers and clinical periodontal parameters.\n\nA total of 100 volunteers identified as having a pro-inflammatory diet (Q3 and Q4) will be included in the study. Individuals will be assigned to two groups. These groups will then be further divided into two groups based on whether or not they will receive anti-inflammatory nutrition education. Group Q3-1 (n=25) will receive non-surgical periodontal treatment and anti-inflammatory nutrition education. Group Q3-2 (n=25) will receive only non-surgical periodontal treatment. Group Q4-1 (n=25) will receive non-surgical periodontal treatment and anti-inflammatory nutrition education. Group Q4-2 (n=25) will receive only non-surgical periodontal treatment. After the periodontal index measurements are completed, the patients will receive non-surgical periodontal treatment. GCF and serum samples, periodontal clinical parameters and Dietary Inflammatory Index will be collected 3 times: at baseline, 1.5 and 3 months after non-surgical periodontal treatment. Levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, total oxidant status (TOS), total antioxidant status (TAS), and C-reactive protein (CRP) will be assessed from these samples. This will investigate the role of anti-inflammatory nutrition in reducing periodontal inflammation and increasing treatment success.",[30],[38,597,598],"diet inflammatory index","anti-inflammatory nutrition","2026-06-18",{"date":579,"type":45},{"date":602,"type":45},"2025-11-22",{"date":604,"type":21},"2026-07-04",{"name":606,"class":52},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":87,"sex":61,"minAge":62,"maxAge":88,"enrollmentInfo":615,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":53},"100641785","salivary-biomarkers-in-periodontal-disease-progression-100641785","NCT07661784","Salivary Biomarkers in Periodontal Disease Progression","Evaluation of Salivary Biomarkers Associated With Bone Remodeling in the Transition From Periodontal Health to Disease","PERIO-BIO","Inclusion Criteria:\n\nAdults aged 18-65 years Systemically healthy individuals Individuals classified as periodontally healthy, gingivitis, or periodontitis according to clinical periodontal examination Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\nPresence of systemic diseases affecting periodontal status (e.g., diabetes mellitus, immunological disorders) Use of antibiotics or anti-inflammatory drugs within the last 3 months History of periodontal treatment within the last 6 months Pregnancy or lactation Smoking (optional ) Any condition that may affect salivary biomarker levels",{"count":616,"type":21},240,"This study aims to evaluate salivary biomarkers associated with bone remodeling during the transition from periodontal health to disease. Periodontal diseases are characterized by chronic inflammation that can lead to connective tissue destruction and alveolar bone loss. Although diagnosis is primarily based on clinical and radiographic findings, these methods may not fully reflect disease activity or progression.\n\nIn this observational study, individuals with periodontal health, gingivitis, and periodontitis will be included. Salivary levels of IL-17, IL-23, IL-6, TGF-β, RANKL, and OPG will be measured using ELISA. The relationship between these biomarkers and periodontal disease stage and grade will be analyzed.\n\nThe results are expected to improve understanding of the biological mechanisms underlying periodontal disease progression and to assess the potential role of salivary biomarkers in early diagnosis and personalized treatment approaches.",[349,619,30],"Gingivitis and Periodontal Diseases",[349,31,30,381,621,622,623,624,625,626,627,628,629],"Bone Remodeling","Interleukin-17 (IL-17)","Interleukin-23 (IL-23)","Interleukin-6 (IL-6)","Transforming Growth Factor Beta (TGF-β)","RANKL","Osteoprotegerin (OPG)","ELISA","Non-invasive Diagnosis","2026-06-16",{"date":548,"type":45},{"date":633,"type":45},"2025-07-10",{"date":635,"type":21},"2026-08-30",{"name":637,"class":52},"Suleyman Demirel University",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":61,"minAge":645,"maxAge":63,"enrollmentInfo":646,"targetDuration":4,"studyType":22,"phases":648,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":656,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":53},"100641352","effectiveness-of-subgingival-instrumentation-on-delaying-end-stage-renal-disease-among-chronic-kidney-disease-patients-100641352","NCT07635797","Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients","Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients: A Non-Randomized Clinical Study","Inclusion Criteria:\n\n* Patients aged 40-70 years.\n* Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents.\n* Diagnosed with Stage IV or V (eGFR between 15-20 mL\u002Fmin\u002F1.73m²).\n* Not undergoing dialysis.\n* Presence of ≥20 natural teeth.\n* Diagnosed with moderate (Stage II) (as per 2017 World Workshop classification) (Interdental CAL at site of greatest loss \\>2mm but \\\u003C5 mm in ≥ 2 non-adjacent teeth).\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients already undergoing haemodialysis or renal transplantation.\n* Patients on insulin therapy or taking SGLT2 inhibitors and GLP-1 receptor agonists.\n* HbA1c level \\>8 %.\n* Any Periodontal therapy within past 6 months.\n* Immunocompromised patients.\n* Any history of tobacco use.\n* Pregnant or lactating women.","40 Years",{"count":647,"type":21},40,[67],"Chronic kidney disease (CKD) and periodontitis share a bidirectional inflammatory relationship, with cytokines such as IL-6, TNF-α, and hsCRP driving progression in both conditions. Non-surgical periodontal therapy (NSPT) has shown reductions in systemic inflammatory markers with emerging evidence of improved renal function, yet robust randomized controlled trials targeting pre-dialysis stage IV-V diabetic CKD patients remain lacking. In the Indian context, where diabetes-related CKD is rapidly rising and access to dialysis is limited, there is a clear lacuna in literature regarding the effectiveness of NSPT in delaying progression to end-stage renal disease. Hence, the present non-randomized clinical study is undertaken to address this gap.",[519,30,651],"End Stage Renal Disease (ESRD)",[519,653,30,654,655],"Subgingival Instrumentation","End Stage Renal Disease","Dialysis",{"date":599,"type":45},{"date":658,"type":21},"2026-07",{"date":660,"type":21},"2027-12",{"name":662,"class":52},"Postgraduate Institute of Dental Sciences Rohtak"]